Skip to content
Screener

BioMarin Pharmaceuticals BMRN Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$989.7MBeat by $57.7M
EPS$1.20Beat by $0.25
Revenue estimate$932.0M
EPS estimate$0.95
“This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide. Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026. Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations.”
Alexander Hardy

Next report

Oct 26, 2026 (in a month)
Revenue estimate$1.0B
EPS estimate$1.35

Financials

Q2 2026

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$12.48B+20.0%
Enterprise value$15.79B+61.2%
P/E34.7×—
P/S3.7×+0.3×

Profitability

See full
Gross margin76.1%-3.4pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Segments

By product

See full
VOXZOGO$252.5M+14.1%
VIMIZIM$194.4M-9.8%
NAGLAZYME$135.3M+5.0%
PALYNZIQ$135.2M+27.6%
GALAFOLD$105.7M—

By segment

See full
Reportable Segment$989.7M+19.9%

FAQ

When did BioMarin Pharmaceuticals report Q2 2026 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q2 2026 earnings on August 6, 2026 after market close.
What were BioMarin Pharmaceuticals's Q2 2026 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $989.7M and eps of $1.20 for Q2 2026.
Did BioMarin Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $932.0M by $57.7M. EPS beat the consensus estimate of $0.95 by $0.25.
How did BioMarin Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.9% from $825.4M a year earlier and eps declined 16.7% from $1.44.
Where can I find BioMarin Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001048477-26-000015) and the 10-Q periodic report (0001048477-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.